 |
The Evolution of the Diagnosis and Management of Painful Diabetic Peripheral Neuropathy CME/CE Author Information and Disclosures Release Date: September 26, 2008; Valid for credit through September 26, 2009 | Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 1.0 ANCC contact hours (0.5 contact hours are in the area of pharmacology);
Pharmacists - 1.0 ACPE continuing education credits for pharmacists (0.1 CEUs) | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME/CE Activity Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Describe the pathophysiology of painful diabetic peripheral neuropathy (DPN)
- Identify the advantages and disadvantages of currently available nonpharmacologic and pharmacologic treatment options for painful DPN
- Evaluate new and emerging treatments for the management of painful DPN
Authors and Disclosures Aaron Vinik, MD, PhD, FCP, FACP
Disclosure: Aaron Vinik, MD, PhD, FCP, FACP, has disclosed that he has served as a consultant to Merck, Eli Lilly, Novartis Pharmaceuticals, Neurometrix, RW Johnson Pharmaceutical Research Institute,
Takeda, AstraZeneca, Sanofi-Aventis, Mitsubishi Pharma America, Inc., and Ansar. Dr. Vinik has also disclosed that he has served on the speaker's bureau for Pfizer, Merck, Eli Lilly, Bristol Meyer Squibb, Novartis Pharmaceuticals, GlaxoSmithKline Beecham, Takeda, AstraZeneca, Sanofi-Aventis, and Ansar. He has also disclosed that he has received grant support from the American Diabetes Association, Neuropathy in Minorities, NASA, Eli Lilly, Parke-Davis, Astamedica,
GlaxoSmithKline Beecham, National Institute of Aging, Merck, Inc., RWJ, Scientific Review Group, Takeda, Juvenile Diabetes Foundation International, Commonwealth Health Research Board, Dynasys, AstraZeneca, Dainippon Pharmaceuticals, Old Dominion University Research Foundation, Medpace/Mitsubishi, National Institutes of Health, and Abbott. David M. Simpson, MD
Disclosure: David M. Simpson, MD, has disclosed
that he has served as an advisor or consultant to Neuroquest, Cephalon, Eli Lilly, Pfizer, Endo, GlaxoSmithKline, and Allergan. Dr. Simpson has also disclosed that he is on the speaker's bureau for Eli Lilly and GlaxoSmithKline. Dr. Simpson has also disclosed that he received grants for clinical research from Neuroquest, Pfizer, and Allergan. Laurie E. Scudder, MS, NP-C
Disclosure: Laurie E. Scudder, MS,
NP-C, has disclosed that she has no relevant financial relationships. Stephanie Kushner, PhD
Disclosure: Stephanie Kushner, PhD, is a member of the professional editorial group at Medscape and has reported no financial relationships relevant to the development of CME activities. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
Medscape is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education for RNs and APNs; 0.5 contact hours are in the area of pharmacology.
Contact This Provider
|
|
 Medscape is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Medscape is accredited by the American Council on Pharmacy Education as a provider of continuing pharmacy education. Medscape designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the American Council on Pharmacy Education (Universal Program Number 461-000-08-058-H01-P).
Contact This Provider
|
|
